Conventional and unconventional mechanisms for soluble guanylyl cyclase signaling

Journal of Cardiovascular Pharmacology

Volumn 67, Issue 5, 2016, Pages 367-372

  Gao, Yuansheng ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

cGMP; cIMP; hypoxic vasoconstriction; nitric oxide; soluble guanylyl cyclase

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; CYCLIC CMP; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC IMP; CYCLIC UMP; GUANYLATE CYCLASE; SOLUBLE GUANYLYL CYCLASE; THYMOQUINONE; UNCLASSIFIED DRUG; VASODILATOR AGENT; CYCLIC AMP; NITRIC OXIDE; NUCLEOSIDE;

CARDIOVASCULAR FUNCTION; CELL HYPOXIA; CELL MEMBRANE PERMEABILITY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME SYNTHESIS; HEART FUNCTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; VASCULAR SMOOTH MUSCLE CELL; VASOCONSTRICTION; VASODILATATION; ANIMAL; METABOLISM;

ANIMALS; CYCLIC AMP; CYCLIC GMP; CYCLIC IMP; HUMANS; NITRIC OXIDE; NUCLEOSIDES; SIGNAL TRANSDUCTION; SOLUBLE GUANYLYL CYCLASE;

EID: 84969704580     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000330     Document Type: Review

References (71)

1. Ashman DF, Lipton R, Melicow MM, et al. Isolation of adenosine 30, 50-mono-phosphate and guanosine 30, 50-monophosphate from rat urine. Biochem Biophys Res Commun. 1963;11:330-334.
2. Hardman JG, Sutherland EW. Guanyl cyclase, an enzyme catalyzing the formation of guanosine 30, 50-monophosphate from guanosine triphosphate. J Biol Chem. 1969;244:6363-6370.
3. Schultz G, Bohme E, Munske K. Guanyl cyclase. Determination of enzyme activity. Life Sci. 1969;8:1323-1332.
4. White AA, Aurbach GD. Detection of guanyl cyclase in mammalian tissues. Biochim Biophys Acta. 1969;191:686-697.
5. Goridis C, Morgan IG. Guanyl cyclase in rat brain subcellular fractions. FEBS Lett. 1973;34:71-73.
6. Kots AY, Martin E, Sharina IG, et al. A short history of cGMP, guanylyl cyclases, and cGMP-dependent protein kinases. Handb Exp Pharmacol. 2009;191:1-14.
7. Gruetter CA, Barry BK, McNamara DB, et al. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res. 1979;5:211-224.
8. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
9. Friebe A, Koesling D. The function of NO-sensitive guanylyl cyclase: what we can learn from genetic mouse models. Nitric Oxide. 2009;21: 149-156.
10. Gao Y. The multiple actions of NO. Pflugers Arch. 2010;459:829-839.
11. Hofmann F, Wegener JW. cGMP-dependent protein kinases (cGK). Methods Mol Biol. 2013;1020:17-50.
12. Maurice DH, Ke H, Ahmad F, et al. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014;13:290-314.
13. Podda MV, Grassi C. New perspectives in cyclic nucleotide-mediated functions in the CNS: the emerging role of cyclic nucleotide-gated (CNG) channels. Pflugers Arch. 2014;466:1241-1257.
14. Kaupp UB, Seifert R. Cyclic nucleotide-gated ion channels. Physiol Rev. 2002;82:769-824.
15. Neitz A, Mergia E, Imbrosci B, et al. Postsynaptic NO/cGMP increases NMDA receptor currents via hyperpolarization-activated cyclic nucleotide-gated channels in the hippocampus. Cereb Cortex. 2014;24: 1923-1936.
16. Beste KY, Burhenne H, Kaever V, et al. Nucleotidyl cyclase activity of soluble guanylyl cyclase a1b1. Biochemistry. 2012;51:194-204.
17. Bähre H, Danker KY, Stasch JP, et al. Nucleotidyl cyclase activity of soluble guanylyl cyclase in intact cells. Biochem Biophys Res Commun. 2014;443:1195-1199.
18. Desch M, Schinner E, Kees F, et al. Cyclic cytidine 30, 50-monophosphate (cCMP) signals via cGMP kinase I. FEBS Lett. 2010;584: 3979-3984.
19. Chen Z, Zhang X, Ying L, et al. Cyclic IMP-synthesized by sGC as a mediator of hypoxic contraction of coronary arteries. Am J Physiol Heart Circ Physiol. 2014;307:H328-H336.
20. Budworth J, Meillerais S, Charles I, et al. Tissue distribution of the human soluble guanylate cyclases. Biochem Biophys Res Commun. 1999;263:696-701.
21. Mergia E, Friebe A, Dangel O, et al. Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system. J Clin Invest. 2006;116:1731-1737.
22. Derbyshire ER, Marletta MA. Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem. 2012;81:533-559.
23. Underbakke ES, Iavarone AT, Chalmers MJ, et al. Nitric oxide-induced conformational changes in soluble guanylate cyclase. Structure. 2014;22: 602-611.
24. Harteneck C, Koesling D, Söling A, et al. Expression of soluble guanylyl cyclase. Catalytic activity requires two enzyme subunits. FEBS Lett. 1990;272:221-223.
25. Zhong F, Pan J, Liu X, et al. A novel insight into the heme and NO/CO binding mechanism of the alpha subunit of human soluble guanylate cyclase. J Biol Inorg Chem. 2011;16:1227-1239.
26. Allerston CK, von Delft F, Gileadi O. Crystal structures of the catalytic domain of human soluble guanylate cyclase. PLoS One. 2013; 8:e57644.
27. Ruiz-Stewart I, Tiyyagura SR, Lin JE, et al. Guanylyl cyclase is an ATP sensor coupling nitric oxide signaling to cell metabolism. Proc Natl Acad Sci U S A. 2004;101:37-42.
28. Surmeli NB, Muskens FM, Marletta MA. The influence of nitric oxide on soluble guanylate cyclase regulation by nucleotides: the role of pseudosymmetric site. J Biol Chem. 2015;290:15570-15580.
29. Fernhoff NB, Derbyshire ER, Marletta MA. A nitric oxide/cysteine interaction mediates the activation of soluble guanylate cyclase. Proc Natl Acad Sci U S A. 2009;106:21602-21607.
30. Martin E, Berka V, Sharina I, et al. Mechanism of binding of NO to soluble guanylyl cyclase: implication for the second NO binding to the heme proximal site. Biochemistry. 2012;51:2737-2746.
31. Zhou Z, Sayed N, Pyriochou A, et al. Protein kinase G phosphorylates soluble guanylyl cyclase on serine 64 and inhibits its activity. Arterioscler Thromb Vasc Biol. 2008;28:1803-1810.
32. Fahey RC, Hunt JS, Windham GC. On the cysteine and cystine content of proteins. Differences between intracellular and extracellular proteins. J Mol Evol. 1977;10:155-160.
33. Sayed N, Baskaran P, Ma X, et al. Desensitization of soluble guanylyl cyclase, the NO receptor, by S-nitrosylation. Proc Natl Acad Sci U S A. 2007;104:12312-12317.
34. Maron BA, Zhang YY, Handy DE, et al. Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinyl thiol oxidation in vascular smooth muscle cells. J Biol Chem. 2009;284:7665-7672.
35. Crassous PA, Couloubaly S, Huang C, et al. Soluble guanylyl cyclase is a target of angiotensin II-induced nitrosative stress in a hypertensive rat model. Am J Physiol Heart Circ Physiol. 2012;303:H597-H604.
36. Dou D, Zheng X, Ying L, et al. Sulfhydryl-dependent dimerization and cGMP-mediated vasodilatation. J Cardiovasc Pharmacol. 2013;62:1-5.
37. Zheng X, Ying L, Liu J, et al. Role of sulfhydryl-dependent dimerization of soluble guanylyl cyclase in relaxation of porcine coronary artery to nitric oxide. Cardiovasc Res. 2011;90:565-572.
38. Ye L, Liu J, Liu H, et al. Sulfhydryl-dependent dimerization of soluble guanylyl cyclase modulates the relaxation of porcine pulmonary arteries to nitric oxide. Pflugers Arch. 2013;465:333-341.
39. Hall CN, Garthwaite J. What is the real physiological NO concentration in vivo? Nitric Oxide. 2009;21:92-103.
40. Ghosh A, Stasch JP, Papapetropoulos A, et al. Nitric oxide and heat shock protein 90 activate soluble guanylate cyclase by driving rapid change in its subunit interactions and heme content. J Biol Chem. 2014;289:15259-15271.
41. Gerassimou C, Kotanidou A, Zhou Z, et al. Regulation of the expression of soluble guanylyl cyclase by reactive oxygen species. Br J Pharmacol. 2007;150:1084-1091.
42. Martín-Garrido A, González-Ramos M, Griera M, et al. H2O2 regulation of vascular function through sGC mRNA stabilization by HuR. Arterioscler Thromb Vasc Biol. 2011;31:567-573.
43. Xu X, Wang S, Liu J, et al. Hypoxia induces downregulation of soluble guanylyl cyclase b1 by miR-34c-5p. J Cell Sci. 2012;125:6117-6126.
44. Vanhoutte PM. Effects of anoxia and glucose depletion on isolated veins of the dog. Am J Physiol. 1976;230:1261-1268.
45. De Mey JG, Vanhoutte PM. Anoxia and endothelium-dependent reactivity of the canine femoral artery. J Physiol. 1983;335:65-74.
46. Rubanyi GM, Vanhoutte PM. Hypoxia releases a vasoconstrictor substance from the canine vascular endothelium. J Physiol. 1985;364: 45-56.
47. Graeser T, Vanhoutte PM. Hypoxic contraction of canine coronary arteries: role of endothelium and cGMP. Am J Physiol Heart Circ Physiol. 1991;261:H1769-H1777.
48. Pearson PJ, Lin PJ, Schaff HV, et al. Augmented endothelium-dependent constriction to hypoxia early and late following reperfusion of the canine coronary artery. Clin Exp Pharmacol Physiol. 1996;23:634-641.
49. Chan CK, Mak J, Gao Y, et al. Endothelium-derived NO, but not cyclic GMP, is required for hypoxic augmentation in isolated porcine coronary arteries. Am J Physiol Heart Circ Physiol. 2011;301:H2313-H2321.
50. Garbers DL, Suddath JL, Hardman JG. Enzymatic formation of inosine 30, 50-monophosphate and of 20-deoxyguanosine 30, 50-monophosphate. Inosinate and deoxyguanylate cyclase activity. Biochim Biophys Acta. 1975;377:174-185.
51. Detremmerie CM, Leung S, Xu A, et al. The endothelium-dependent, soluble guanylyl cyclase-dependent augmentation caused by thymoquinone in isolated porcine arteries is mediated by cIMP. FASEB J. 2014;28 (1 suppl):1146.6.
52. Leung S, Detremmerie CM, Li Z, et al. Thymoquinone causes endothelium-dependent augmentation of contraction depending on activation of soluble guanylyl cyclase. J Vasc Res. 2013;50(suppl 1):56.
53. Sousa EH, Garay PA, Tinianow JN, et al. Development of a spectrophotometric assay for cyclase activity. Anal Biochem. 2006;348:57-63.
54. Hoenicka M, Becker EM, Apeler H, et al. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. J Mol Med (Berl). 1999;77:14-23.
55. Reinecke D, Burhenne H, Sandner P, et al. Human cyclic nucleotide phosphodiesterases possess a much broader substrate-specificity than previously appreciated. FEBS Lett. 2011;585:3259-3262.
56. Leung S, Gao Y, Vanhoutte PM. 30, 50-cIMP as potential second messenger in the vascular wall. Handb Exp Pharmacol. In press.
57. Sakumi K, Abolhassani N, Behmanesh M, et al. ITPA protein, an enzyme that eliminates deaminated purine nucleoside triphosphates in cells. Mutat Res. 2010;703:43-50.
58. Schofield AV, Bernard O. Rho-associated coiled-coil kinase (ROCK) signaling and disease. Crit Rev Biochem Mol Biol. 2013; 48:301-316.
59. Gao Y, Portugal AD, Negash S, et al. Role of Rho kinases in PKGmediated relaxation of pulmonary arteries of fetal lambs exposed to chronic high altitude hypoxia. Am J Physiol Lung Cell Mol Physiol. 2007;292:L678-L684.
60. Wolter S, Dove S, Golombek M, et al. N4-monobutyryl-cCMP activates PKA RIa and PKA RIIa more potently and with higher efficacy than PKG Ia in vitro but not in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2014;387:1163-1175.
61. Hartwig C, Bähre H, Wolter S, et al. cAMP, cGMP, cCMP and cUMP concentrations across the tree of life: high cCMP and cUMP levels in astrocytes. Neurosci Lett. 2014;579:183-187.
62. Bähre H, Hartwig C, Munder A, et al. cCMP and cUMP occur in vivo. Biochem Biophys Res Commun. 2015;460:909-914.
63. Seifert R, Schneider EH, Bähre H. From canonical to non-canonical cyclic nucleotides as second messengers: pharmacological implications. Pharmacol Ther. 2015;148:154-184.
64. Zong X, Krause S, Chen CC, et al. Regulation of hyperpolarizationactivated cyclic nucleotide-gated (HCN) channel activity by cCMP. J Biol Chem. 2012;287:26506-26512.
65. Akimoto M, Zhang Z, Boulton S, et al. A mechanism for the autoinhibition of hyperpolarization-activated cyclic nucleotide-gated (HCN) channel opening and its relief by cAMP. J Biol Chem. 2014;289: 22205-22220.
66. Wolter S, Golombek M, Seifert R. Differential activation of cAMP-and cGMP-dependent protein kinases by cyclic purine and pyrimidine nucleotides. Biochem Biophys Res Commun. 2011;415:563-566.
67. Wolfertstetter S, Reinders J, Schwede F, et al. Interaction of cCMP with the cGK, cAK and MAPK kinases in murine tissues. PLoS One. 2015; 10:e0126057.
68. Beste KY, Seifert R. cCMP, cUMP, cTMP, cIMP and cXMP as possible second messengers: development of a hypothesis based on studies with soluble guanylyl cyclase a(1)b(1). Biol Chem. 2013;394: 261-270.
69. Gao Y, Chen Z, Leung SWS, et al. Hypoxic vasospasm mediated by cIMP: when soluble guanylyl cyclase turns bad. J Cardiovasc Pharmacol. 2015;65:545-548.
70. Aley PK, Singh N, Brailoiu GC, et al. Nicotinic acid adenine dinucleotide phosphate (NAADP) is a second messenger in muscarinic receptorinduced contraction of guinea pig trachea. J Bio Chem. 2013;288: 10986-10993.
71. Sutherland EW, Robison GA, Butcher RW. Some aspects of the biological role of adenosine 30, 50-monophosphate (Cyclic AMP). Circulation. 1968;37:279-306.